Navigation Links
New marker of drug response may speed pace of lung cancer prevention trials
Date:1/8/2013

Testing medicines to prevent lung cancer requires treating many thousands of high-risk individuals and then waiting 5, 10 or 15 years to discover which of them develop cancer and which, if any, experience survival benefit from the treatment. A University of Colorado Cancer Center study recently published in the journal Cancer Prevention Research proposes a possible waypoint on the way to benefit, which if validated, could dramatically reduce the number of patients needed and time required to test drugs for lung cancer prevention.

"Chemoprevention is an important approach that has been way behind in terms of scientific advances for lung cancer," says Fred R. Hirsch, MD, PhD, investigator at the CU Cancer Center and professor of medical oncology and pathology at the CU School of Medicine. "If we could find a surrogate endpoint for lung cancer mortality an intermediate endpoint it would make it much easier to conduct smaller trials in much shorter time."

The original intent of the study was to discover certain microRNAs whose level of expression might predict patients likely to respond to the possible chemopreventive drug, Iloprost. If an especially high or low microRNA expression predicted response, it would allow researchers to test the drug only in the population most likely to benefit. Unfortunately, while levels of seven miRNAs were found to be correlated with the appearance of lung cancer, none predicted response to the drug.

It might have been a dead-end study if it weren't for microRNA-34c.

To a striking degree, changes in the expression of this molecule six months after treatment correlated with benefit from the drug seen much later. In those who later showed benefit, microRNA-34c expression was down six months after treatment; in patients who showed no benefit, microRNA-34c expression remained unchanged.

"Instead of waiting for an endpoint 15 years in the future, we could potentially discover the effectiveness of chemopreventive agents only six months after treatment. It would speed up the pace of discovery and eventually bring new chemopreventive agents much faster to the market," Hirsch says.

Hirsch cautions that his discovery, with CU Cancer Center colleagues including Celine Mascaux, MD, PhD, of this potential intermediate endpoint is just that: potential. Further work is needed to validate the predictive power of miRNA-34c in showing chemopreventive response. But Hirsch and colleagues are hopeful not only that miRNA-34c could be this predictive waypoint, but that the cutting edge technique of looking beneath genes, beneath even RNA and mRNA into the molecular world of microRNA will help them discover the roots of the disease.

"The approach is new and it needs to be further explored," Hirsch says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Is the detection of early markers of Epstein Barr virus of diagnostic value?
2. BioFortis Inc., Introduces Next Generation Biobanking Software Platform for Biomarker-Based Clinical Research
3. U of M researchers: Newly discovered genetic markers could signal colon cancer development
4. Molecular and protein markers discovered for liver transplant failure from hepatitis C
5. Color-coded markers may help doctors diagnose neural diseases through the eyes
6. New biomarker for common lung cancer predicts responses to chemotherapy
7. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
8. Researchers identify genetic markers to predict male fertility
9. Tufts Medical Center researchers finds marker in premies saliva predicts readiness to feed by mouth
10. Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease
11. Trial seeks improved lung-cancer screening by combining imaging and biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
(Date:3/18/2016)... , March 18, 2016 --> ... of Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and ... security companies in the border security market and the continuing ... and Europe has led visiongain to ... improved success. --> defence & security companies ...
Breaking Biology News(10 mins):
(Date:5/23/2016)... BOSTON and LONDON , May 23, ... 10 Could See Frontage Boost Efficiency by 40% - ... - Frontage Enforce Quality, Compliance and Traceability Within the ... (CRO) with labs in the United States ... 10 to be deployed across its laboratory facilities. In addition ...
(Date:5/20/2016)... CA (PRWEB) , ... May 20, 2016 , ... The ... 10 of its most experienced veterinary clients have treated over 100 of their own ... edge technology to provide the highest level of care for their patients. , ...
(Date:5/19/2016)... ... May 19, 2016 , ... Anton Paar USA, located in Ashland, ... building is complete. The new structure adds a third office building to the current ... purchased 2.4 acres of land, along with office space adjacent to the previous ...
(Date:5/19/2016)... , May 19, 2016 ... PINK: RGBP) and (OTC PINK: RGBPP) announced today initiation ... the first cord blood based cancer immunotherapeutic product ... patent application, Regen described a generation of cord ... potentiated by gene silencing.  The product in development ...
Breaking Biology Technology: